Cargando…
Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer
In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617389/ https://www.ncbi.nlm.nih.gov/pubmed/37916184 http://dx.doi.org/10.1055/a-2074-0125 |
_version_ | 1785129597374824448 |
---|---|
author | Lux, Michael P. Hartkopf, Andreas D. Fehm, Tanja N. Welslau, Manfred Müller, Volkmar Schütz, Florian Fasching, Peter A. Janni, Wolfgang Witzel, Isabell Thomssen, Christoph Beierlein, Milena Belleville, Erik Untch, Michael Thill, Marc Tesch, Hans Ditsch, Nina Aktas, Bahriye Banys-Paluchowski, Maggie Kolberg-Liedtke, Cornelia Wöckel, Achim Kolberg, Hans-Christian Harbeck, Nadia Bartsch, Rupert Schneeweiss, Andreas Ettl, Johannes Würstlein, Rachel Krug, David Taran, Florin-Andrei Lüftner, Diana Stickeler, Elmar |
author_facet | Lux, Michael P. Hartkopf, Andreas D. Fehm, Tanja N. Welslau, Manfred Müller, Volkmar Schütz, Florian Fasching, Peter A. Janni, Wolfgang Witzel, Isabell Thomssen, Christoph Beierlein, Milena Belleville, Erik Untch, Michael Thill, Marc Tesch, Hans Ditsch, Nina Aktas, Bahriye Banys-Paluchowski, Maggie Kolberg-Liedtke, Cornelia Wöckel, Achim Kolberg, Hans-Christian Harbeck, Nadia Bartsch, Rupert Schneeweiss, Andreas Ettl, Johannes Würstlein, Rachel Krug, David Taran, Florin-Andrei Lüftner, Diana Stickeler, Elmar |
author_sort | Lux, Michael P. |
collection | PubMed |
description | In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP inhibitors. This review summarizes and evaluates the latest study results that have been published in recent months. This includes the overall survival data of the Destiny-Breast03 study, the first analysis of the CAPItello-291 study, the comparison of CDK4/6 inhibitor treatment with chemotherapy in the first line of therapy (RIGHT Choice study), the first analysis of the Destiny-Breast02 study in the treatment setting after T-DM1 treatment, and the first analysis of the Serena-2 study. Most of these studies have the potential to significantly change the therapeutic landscape for patients with advanced breast carcinoma and show that the continued rapid development of new therapies is always producing new results. |
format | Online Article Text |
id | pubmed-10617389 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-106173892023-11-01 Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer Lux, Michael P. Hartkopf, Andreas D. Fehm, Tanja N. Welslau, Manfred Müller, Volkmar Schütz, Florian Fasching, Peter A. Janni, Wolfgang Witzel, Isabell Thomssen, Christoph Beierlein, Milena Belleville, Erik Untch, Michael Thill, Marc Tesch, Hans Ditsch, Nina Aktas, Bahriye Banys-Paluchowski, Maggie Kolberg-Liedtke, Cornelia Wöckel, Achim Kolberg, Hans-Christian Harbeck, Nadia Bartsch, Rupert Schneeweiss, Andreas Ettl, Johannes Würstlein, Rachel Krug, David Taran, Florin-Andrei Lüftner, Diana Stickeler, Elmar Geburtshilfe Frauenheilkd In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP inhibitors. This review summarizes and evaluates the latest study results that have been published in recent months. This includes the overall survival data of the Destiny-Breast03 study, the first analysis of the CAPItello-291 study, the comparison of CDK4/6 inhibitor treatment with chemotherapy in the first line of therapy (RIGHT Choice study), the first analysis of the Destiny-Breast02 study in the treatment setting after T-DM1 treatment, and the first analysis of the Serena-2 study. Most of these studies have the potential to significantly change the therapeutic landscape for patients with advanced breast carcinoma and show that the continued rapid development of new therapies is always producing new results. Georg Thieme Verlag KG 2023-06-06 /pmc/articles/PMC10617389/ /pubmed/37916184 http://dx.doi.org/10.1055/a-2074-0125 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Lux, Michael P. Hartkopf, Andreas D. Fehm, Tanja N. Welslau, Manfred Müller, Volkmar Schütz, Florian Fasching, Peter A. Janni, Wolfgang Witzel, Isabell Thomssen, Christoph Beierlein, Milena Belleville, Erik Untch, Michael Thill, Marc Tesch, Hans Ditsch, Nina Aktas, Bahriye Banys-Paluchowski, Maggie Kolberg-Liedtke, Cornelia Wöckel, Achim Kolberg, Hans-Christian Harbeck, Nadia Bartsch, Rupert Schneeweiss, Andreas Ettl, Johannes Würstlein, Rachel Krug, David Taran, Florin-Andrei Lüftner, Diana Stickeler, Elmar Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer |
title | Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer |
title_full | Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer |
title_fullStr | Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer |
title_full_unstemmed | Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer |
title_short | Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer |
title_sort | update breast cancer 2023 part 2 – advanced-stage breast cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617389/ https://www.ncbi.nlm.nih.gov/pubmed/37916184 http://dx.doi.org/10.1055/a-2074-0125 |
work_keys_str_mv | AT luxmichaelp updatebreastcancer2023part2advancedstagebreastcancer AT hartkopfandreasd updatebreastcancer2023part2advancedstagebreastcancer AT fehmtanjan updatebreastcancer2023part2advancedstagebreastcancer AT welslaumanfred updatebreastcancer2023part2advancedstagebreastcancer AT mullervolkmar updatebreastcancer2023part2advancedstagebreastcancer AT schutzflorian updatebreastcancer2023part2advancedstagebreastcancer AT faschingpetera updatebreastcancer2023part2advancedstagebreastcancer AT janniwolfgang updatebreastcancer2023part2advancedstagebreastcancer AT witzelisabell updatebreastcancer2023part2advancedstagebreastcancer AT thomssenchristoph updatebreastcancer2023part2advancedstagebreastcancer AT beierleinmilena updatebreastcancer2023part2advancedstagebreastcancer AT bellevilleerik updatebreastcancer2023part2advancedstagebreastcancer AT untchmichael updatebreastcancer2023part2advancedstagebreastcancer AT thillmarc updatebreastcancer2023part2advancedstagebreastcancer AT teschhans updatebreastcancer2023part2advancedstagebreastcancer AT ditschnina updatebreastcancer2023part2advancedstagebreastcancer AT aktasbahriye updatebreastcancer2023part2advancedstagebreastcancer AT banyspaluchowskimaggie updatebreastcancer2023part2advancedstagebreastcancer AT kolbergliedtkecornelia updatebreastcancer2023part2advancedstagebreastcancer AT wockelachim updatebreastcancer2023part2advancedstagebreastcancer AT kolberghanschristian updatebreastcancer2023part2advancedstagebreastcancer AT harbecknadia updatebreastcancer2023part2advancedstagebreastcancer AT bartschrupert updatebreastcancer2023part2advancedstagebreastcancer AT schneeweissandreas updatebreastcancer2023part2advancedstagebreastcancer AT ettljohannes updatebreastcancer2023part2advancedstagebreastcancer AT wurstleinrachel updatebreastcancer2023part2advancedstagebreastcancer AT krugdavid updatebreastcancer2023part2advancedstagebreastcancer AT taranflorinandrei updatebreastcancer2023part2advancedstagebreastcancer AT luftnerdiana updatebreastcancer2023part2advancedstagebreastcancer AT stickelerelmar updatebreastcancer2023part2advancedstagebreastcancer |